Search results
Moderna’s sales from its only product, the COVID-19 vaccine, fell 91% from last year
Fortune via Yahoo Finance· 20 hours agoWhat’s more...
Flu vs COVID: Stark Disparity in Vaccination and Deaths
Medscape· 2 days agoIn the first half of 2023, COVID-19 killed 42,670 people in the United States, while the flu killed...
Moderna COVID vaccine sales plummet 91 percent - The Boston Globe
The Boston Globe· 1 day agoShares of Moderna rose more than 7 percent in early morning trading. Pfizer, the New York-based drug...
Supreme Court rejected military chaplains' lawsuit saying their careers were ruined after refusing...
Business Insider· 2 days agoThe Supreme Court denied military chaplains' lawsuit claiming retaliation for refusing the COVID-19 ...
Moderna Breaks Out For The First Time In A Year After Covid Shot Wallops Sales Views
Investor's Business Daily· 22 hours agoNow, investors are zeroing...projected for the first half of 2024. Moderna stock analysts project...
Earnings call: Pfizer raises 2024 EPS outlook despite revenue decline By Investing.com
Investing.com· 2 days agoDespite a 19% decline in total company revenues to $14.9 billion, primarily due to the reduced...
Why I'm Buying This Beaten-Down, High-Yield Dividend Stock Hand Over Fist
Motley Fool via Yahoo Finance· 3 days agoThe Stock Advisor service has more than quadrupled the return...since 2002*. *Stock Advisor returns...
Here's Why Pfizer (PFE) is a Strong Momentum Stock
Zacks· 13 hours agoThe popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks ...
Moderna Stock Jumps After Scoring an Earnings Beat. Next Up? Its RSV Shot.
Barrons.com· 1 day agoModerna anticipates offering a respiratory syncytial virus vaccine later this year, to compete...
Moderna posts better-than-expected quarterly results as it looks to fall RSV vaccine launch
Market Watch· 1 day agoThe company reported a first-quarter net loss of $1.175 billion, or $3.07 a share, after net income...
